Citadel Advisors
XBIT icon

Citadel Advisors’s XBiotech XBIT Stock Holding History

Citadel Advisors’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.1K Buy
+29,192
New +$70.6K ﹤0.01% 12963
2025
Q4 		– Sell
-42,816
Closed -$106K – 14260
2025
Q3 		$114K Buy
42,816
+10,333
+32% +$30.6K ﹤0.01% 11753
2025
Q2 		$96.5K Buy
+32,483
New +$94.4K ﹤0.01% 11382
2025
Q1 		– Sell
-13
Closed -$51 – 15709
2024
Q4 		$51 Buy
+13
New +$89 ﹤0.01% 14391
2024
Q3 		– Sell
-4,890
Closed -$25.1K – 15379
2024
Q2 		$25.1K Sell
4,890
-2,152
-31% -$16.6K ﹤0.01% 12434
2024
Q1 		$57.3K Sell
7,042
-5,232
-43% -$30K ﹤0.01% 12045
2023
Q4 		$49.1K Buy
12,274
+1,621
+15% +$6.46K ﹤0.01% 11796
2023
Q3 		$43.9K Sell
10,653
-5,946
-36% -$29.8K ﹤0.01% 11899
2023
Q2 		$98.6K Sell
16,599
-3,775
-19% -$17K ﹤0.01% 10964
2023
Q1 		$70.3K Buy
20,374
+8,649
+74% +$32.2K ﹤0.01% 11725
2022
Q4 		$41.2K Buy
+11,725
New +$40K ﹤0.01% 12376
2022
Q3 		– Sell
-80,884
Closed -$455K – 13734
2022
Q2 		$455K Buy
80,884
+39,615
+96% +$267K ﹤0.01% 8855
2022
Q1 		$356K Buy
+41,269
New +$414K ﹤0.01% 10189
2021
Q4 		– Sell
-47,828
Closed -$619K – 14881
2021
Q3 		$619K Buy
+47,828
New +$762K ﹤0.01% 9358
2020
Q4 		– Sell
-11,467
Closed -$211K – 11605
2020
Q3 		$219K Buy
+11,467
New +$198K ﹤0.01% 8667
2020
Q2 		– Sell
-34,134
Closed -$363K – 10609
2020
Q1 		$363K Buy
+34,134
New +$556K ﹤0.01% 6990
2019
Q3 		– Sell
-19,227
Closed -$146K – 9829
2019
Q2 		$146K Buy
+19,227
New +$167K ﹤0.01% 8371
2017
Q3 		– Sell
-19,661
Closed -$92.8K – 8130
2017
Q2 		$92K Buy
+19,661
New +$188K ﹤0.01% 6939

Other funds holding XBIT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors's XBIT Position: Q2 2026 in Review

Citadel Advisors opened a new position in XBiotech (XBIT) in Q2 2026: 29,192 shares worth $67.1K. The stake represents ﹤0.01% of the portfolio and ranks #12963 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in XBIT as recently as Q3 2025.

Citadel Advisors first reported a position in XBIT in Q2 2017 and has held it in 18 quarters since. The position peaked at $619K in Q3 2021. 36 funds tracked by Wall St. Rank hold XBIT as of Q2 2026.

  • Citadel Advisors held 29,192 shares of XBiotech worth $67.1K as of Q2 2026.
  • XBiotech was a new Citadel Advisors position in Q2 2026.
  • XBiotech made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12963 holding.
  • Citadel Advisors first reported a position in XBiotech in Q2 2017 and has held it in 18 quarters since.
  • Citadel Advisors's XBiotech position peaked at $619K in Q3 2021.
  • 36 funds tracked by Wall St. Rank held XBiotech as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.